Julio C Fernandes

List of Publications by Year
in descending order

78	5,737	117571 34	74108 75
papers	citations	h-index	g-index

80	80	80	6964
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Use of IMMPACT Recommendations to Explore Pain Phenotypes in People with Knee Osteoarthritis. Pain Medicine, 2022, 23, 1708-1716.	0.9	6
2	Chitosan-Based Nanogels: Synthesis and Toxicity Profile for Drug Delivery to Articular Joints. Nanomaterials, 2022, 12, 1337.	1.9	15
3	Advanced practice physiotherapy for adults with spinal pain: a systematic review with meta-analysis. European Spine Journal, 2021, 30, 990-1003.	1.0	9
4	The pathophysiology of immunoporosis: innovative therapeutic targets. Inflammation Research, 2021, 70, 859-875.	1.6	12
5	Trajectories of Follow-up Compliance in a Fracture Liaison Service and Their Predictors: A Longitudinal Group-Based Trajectory Analysis. Health Services Research and Managerial Epidemiology, 2021, 8, 233339282110470.	0.5	1
6	Single session compared with multiple sessions of education and exercise for older adults with spinal pain in an advanced practice physiotherapy model of care: protocol for a randomised controlled trial. BMJ Open, 2021, 11, e053004.	0.8	0
7	Economic evaluation of advanced practice physiotherapy models of care: a systematic review with meta-analyses. BMC Health Services Research, 2021, 21, 1214.	0.9	7
8	Performance of a Fracture Liaison Service in an Orthopaedic Setting. Journal of Bone and Joint Surgery - Series A, 2020, 102, 486-494.	1.4	12
9	Evidence Supporting the Safety of Pegylated Diethylaminoethyl-Chitosan Polymer as a Nanovector for Gene Therapy Applications . International Journal of Nanomedicine, 2020, Volume 15, 6183-6200.	3.3	17
10	Patient Healthcare Trajectory and its Impact on the Cost-Effectiveness of Fracture Liaison Services. Journal of Bone and Mineral Research, 2020, 36, 459-468.	3.1	10
11	Persistence and compliance to osteoporosis therapy in a fracture liaison service: a prospective cohort study. Archives of Osteoporosis, 2019, 14, 87.	1.0	15
12	In vitro and in vivo assessment of the proresolutive and antiresorptive actions of resolvin D1: relevance to arthritis. Arthritis Research and Therapy, 2019, 21, 72.	1.6	39
13	Rationale, study design, and descriptive data of the Lucky Boneâ„¢ Fracture Liaison Service. Archives of Osteoporosis, 2019, 14, 19.	1.0	8
14	Incidence of symptomatic venous thromboembolism in 2372 knee and hip replacement patients after discharge: data from a thromboprophylaxis registry in Montreal, Canada. Vascular Health and Risk Management, 2018, Volume 14, 81-89.	1.0	13
15	Diethylaminoethyl- chitosan as an efficient carrier for siRNA delivery: Improving the condensation process and the nanoparticles properties. International Journal of Biological Macromolecules, 2018, 119, 186-197.	3.6	27
16	Simulation of acoustic guided wave propagation in cortical bone using a semi-analytical finite element method. Journal of the Acoustical Society of America, 2017, 141, 2538-2547.	0.5	21
17	An overview of the role of lipid peroxidation-derived 4-hydroxynonenal in osteoarthritis. Inflammation Research, 2017, 66, 637-651.	1.6	32
18	Elucidating the Role of Protandim and 6â€Gingerol in Protection Against Osteoarthritis. Journal of Cellular Biochemistry, 2017, 118, 1003-1013.	1.2	43

#	Article	IF	Citations
19	The role of resolvin D1 in the regulation of inflammatory and catabolic mediators in osteoarthritis. Inflammation Research, 2016, 65, 635-645.	1.6	53
20	A lateral approach defect closure technique with deep fascia flap for valgus knee TKA. Journal of Orthopaedic Surgery and Research, 2015, 10, 173.	0.9	4
21	New Evidence Implicating 4â€Hydroxynonenal in the Pathogenesis of Osteoarthritis In Vivo. Arthritis and Rheumatology, 2014, 66, 2461-2471.	2.9	20
22	A novel inÂvitro system for intracellular delivery of nonviral DNA. Journal of Orthopaedic Translation, 2014, 2, 157-164.	1.9	4
23	Sorbitol-modified hyaluronic acid reduces oxidative stress, apoptosis and mediators of inflammation and catabolism in human osteoarthritic chondrocytes. Inflammation Research, 2014, 63, 691-701.	1.6	47
24	Response to 'Ramipril attenuates lipid peroxidation and cardiac fibrosis in an experimental model of rheumatoid arthritis' - authors' reply. Arthritis Research and Therapy, 2013, 15, 406.	1.6	0
25	Validation of an advanced practice physiotherapy model of care in an orthopaedic outpatient clinic. BMC Musculoskeletal Disorders, 2013, 14, 162.	0.8	84
26	Treatment of Prosthetic Joint Infections: Validation of a Surgical Algorithm and Proposal of a Simplified Alternative. Journal of Arthroplasty, 2013, 28, 395-400.	1.5	16
27	Dexamethasone shifts bone marrow stromal cells from osteoblasts to adipocytes by C/EBPalpha promoter methylation. Cell Death and Disease, 2013, 4, e832-e832.	2.7	139
28	Polyethylenimine600-β-cyclodextrin: a promising nanopolymer for nonviral gene delivery of primary mesenchymal stem cells. International Journal of Nanomedicine, 2013, 8, 1935.	3.3	15
29	Linear polyethylenimine produced by partial acid hydrolysis of poly(2-ethyl-2-oxazoline) for DNA and siRNA delivery in vitro. International Journal of Nanomedicine, 2013, 8, 4091.	3.3	23
30	Polymeric Systems as Nanodevices for siRNA Delivery. Current Gene Therapy, 2013, 13, 358-369.	0.9	9
31	Prognostic Factors for Predicting Outcomes After Intramedullary Nailing of the Tibia. Journal of Bone and Joint Surgery - Series A, 2012, 94, 1786-1793.	1.4	115
32	Efficient Nonviral Gene Therapy Using Folate-Targeted Chitosan-DNA Nanoparticles In Vitro. ISRN Pharmaceutics, 2012, 2012, 1-9.	1.0	14
33	Low molecular weight chitosan conjugated with folate for siRNA delivery in vitro: optimization studies. International Journal of Nanomedicine, 2012, 7, 5833.	3.3	50
34	Ramipril attenuates lipid peroxidation and cardiac fibrosis in an experimental model of rheumatoid arthritis. Arthritis Research and Therapy, 2012, 14, R223.	1.6	29
35	Uptake mechanisms of non-viral gene delivery. Journal of Controlled Release, 2012, 158, 371-378.	4.8	254
36	Inhibition of inducible nitric oxide synthase prevents lipid peroxidation in osteoarthritic chondrocytes. Journal of Cellular Biochemistry, 2012, 113, 2256-2267.	1.2	45

#	Article	IF	Citations
37	siRNA therapy for cancer and non-lethal diseases such as arthritis and osteoporosis. Expert Opinion on Biological Therapy, 2011, 11, 5-16.	1.4	14
38	Economic Evaluation of Reamed versus Unreamed Intramedullary Nailing in Patients with Closed and Open Tibial Fractures: Results from the Study to Prospectively Evaluate Reamed Intramedullary Nails in Patients with Tibial Fractures (SPRINT). Value in Health, 2011, 14, 450-457.	0.1	16
39	Outcomes assessment in the SPRINT multicenter tibial fracture trial: Adjudication committee size has trivial effect on trial results. Journal of Clinical Epidemiology, 2011, 64, 1023-1033.	2.4	8
40	Fluid Lavage of Open Wounds (FLOW): A Multicenter, Blinded, Factorial Pilot Trial Comparing Alternative Irrigating Solutions and Pressures in Patients With Open Fractures. Journal of Trauma, 2011, 71, 596-606.	2.3	31
41	Polycation-Based Gene Therapy: Current Knowledge and New Perspectives. Current Gene Therapy, 2011, 11, 288-306.	0.9	96
42	Trabecular Metal Used for Major Bone Loss in Acetabular Hip Revision. Journal of Arthroplasty, 2011, 26, 1245-1250.	1.5	68
43	Elucidation of molecular mechanisms underlying the protective effects of thymoquinone against rheumatoid arthritis. Journal of Cellular Biochemistry, 2011, 112, 107-117.	1.2	113
44	Nuclear receptor retinoid-related orphan receptor Î±1 modulates the metabolic activity of human osteoblasts. Journal of Cellular Biochemistry, 2011, 112, 2160-2169.	1.2	16
45	Hydrodynamic Delivery of Chitosan-Folate-DNA Nanoparticles in Rats with Adjuvant-Induced Arthritis. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-9.	3.0	18
46	Finite element analysis of an acetabular trial implant. , 2010, 2010, 3930-3.		1
47	Perturbation of adhesion molecule-mediated chondrocyte-matrix interactions by 4-hydroxynonenal binding: implication in osteoarthritis pathogenesis. Arthritis Research and Therapy, 2010, 12, R201.	1.6	32
48	Pluronic F-127 as a Cell Carrier for Bone Tissue Engineering. Journal of Biomaterials Applications, 2009, 24, 275-287.	1.2	24
49	Progress and Prospects of Chitosan and Its Derivatives as Non-Viral Gene Vectors in Gene Therapy. Current Gene Therapy, 2009, 9, 495-502.	0.9	39
50	Comparison of direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate: a population-based study. Osteoporosis International, 2009, 20, 1571-1581.	1.3	15
51	An active role for soluble and membrane intercellular adhesion molecule-1 in osteoclast activity in vitro. Journal of Bone and Mineral Metabolism, 2008, 26, 543-550.	1.3	10
52	Bone-protective Effects of Nonviral Gene Therapy With Folateâ€“Chitosan DNA Nanoparticle Containing Interleukin-1 Receptor Antagonist Gene in Rats With Adjuvant-induced Arthritis. Molecular Therapy, 2008, 16, 1243-1251.	3.7	88
53	4-Hydroxynonenal induces apoptosis in human osteoarthritic chondrocytes: the protective role of glutathione-S-transferase. Arthritis Research and Therapy, 2008, 10, R107.	1.6	82
54	Gene therapy of arthritis and orthopaedic disorders: current experimental approaches in China and in Canada. Expert Opinion on Biological Therapy, 2008, 8, 1337-1346.	1.4	2

#	Article	IF	Citations
55	Differential regulation of cyclooxygenase-2 and inducible nitric oxide synthase by 4-hydroxynonenal in human osteoarthritic chondrocytes through ATF-2/CREB-1 transactivation and concomitant inhibition of NF-ÎºB signaling cascade. Journal of Cellular Biochemistry, 2007, 100, 1217-1231.	1.2	52
56	Alterations of metabolic activity in human osteoarthritic osteoblasts by lipid peroxidation end product 4-hydroxynonenal. Arthritis Research and Therapy, 2006, 8, R159.	1.6	49
57	Synthesis and Characterization of Phosphorylcholine-Substituted Chitosans Soluble in Physiological pH Conditions. Biomacromolecules, 2006, 7, 3151-3156.	2.6	70
58	Characterization of folate-chitosan-DNA nanoparticles for gene therapy. Biomaterials, 2006, 27, 2060-2065.	5.7	374
59	Chitosan Nanoparticles for Non-Viral Gene Therapy. ACS Symposium Series, 2006, , 177-200.	0.5	7
60	Production of lipid peroxidation products in osteoarthritic tissues: New evidence linking 4-hydroxynonenal to cartilage degradation. Arthritis and Rheumatism, 2006, 54, 271-281.	6.7	75
61	Synthetic and Natural Polycations for Gene Therapy: State of the Art and New Perspectives. Current Gene Therapy, 2006, 6, 59-71.	0.9	92
62	Metalloproteinase and cytokine production by THP-1 macrophages following exposure to chitosan-DNA nanoparticles. Biomaterials, 2005, 26, 961-970.	5.7	85
63	Involvement of ICAM-1 in bone metabolism: a potential target in the treatment of bone diseases?. Expert Opinion on Biological Therapy, 2005, 5, 313-320.	1.4	18
64	Endothelin-1 in osteoarthritic chondrocytes triggers nitric oxide production and upregulates collagenase production. Arthritis Research, 2005, 7, R324.	2.0	32
65	Expression of ICAM-1 by osteoblasts in healthy individuals and in patients suffering from osteoarthritis and osteoporosis. Bone, 2004, 35, 463-470.	1.4	37
66	Chitosan-DNA nanoparticles as non-viral vectors in gene therapy: strategies to improve transfection efficacy. European Journal of Pharmaceutics and Biopharmaceutics, 2004, 57, 1-8.	2.0	486
67	In vivo selective inhibition of mitogen-activated protein kinase kinase 1/2 in rabbit experimental osteoarthritis is associated with a reduction in the development of structural changes. Arthritis and Rheumatism, 2003, 48, 1582-1593.	6.7	112
68	Mesenchymal stem cells, MG63 and HEK293 transfection using chitosan-DNA nanoparticles. Biomaterials, 2003, 24, 1255-1264.	5.7	351
69	The role of cytokines in osteoarthritis pathophysiology. Biorheology, 2002, 39, 237-46.	1.2	713
70	Metabolic activity of osteoblasts from periprosthetic trabecular bone in failed total hip arthroplasties and osteoarthritis as markers of osteolysis and loosening. Journal of Rheumatology, 2002, 29, 1437-45.	1.0	9
71	In vivo dual inhibition of cyclooxygenase and lipoxygenase by ML-3000 reduces the progression of experimental osteoarthritis: Suppression of collagenase 1 and interleukin-1? synthesis. Arthritis and Rheumatism, 2001, 44, 2320-2330.	6.7	100
72	Gene Therapy for Osteoarthritis. Clinical Orthopaedics and Related Research, 2000, 379, S262-S272.	0.7	17

#	Article	IF	Citations
73	Selective inhibition of inducible nitric oxide synthase reduces progression of experimental osteoarthritis in vivo: Possible link with the reduction in chondrocyte apoptosis and caspase 3 level. Arthritis and Rheumatism, 2000, 43, 1290-1299.	6.7	217
74	In Vivo Transfer of Interleukin-1 Receptor Antagonist Gene in Osteoarthritic Rabbit Knee Joints. American Journal of Pathology, 1999, 154, 1159-1169.	1.9	218
75	Reduced progression of experimental osteoarthritis in vivo by selective inhibition of inducible nitric oxide synthase. Arthritis and Rheumatism, 1998, 41, 1275-1286.	6.7	318
76	Effects of tenidap on the progression of osteoarthritic lesions in a canine experimental model. Suppression of metalloprotease and interleukin-1 activity. Arthritis and Rheumatism, 1997, 40, 284-294.	6.7	28
77	Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis. Suppression of collagenase-1 expression. Arthritis and Rheumatism, 1996, 39, 1535-1544.	6.7	338
78	Effects of tenidap on canine experimental osteoarthritis i. morphologic and metalloprotease analysis. Arthritis and Rheumatism, 1995, 38, 1290-1303.	6.7	58